Drug Profile
Interferon-alpha gene therapy
Latest Information Update: 19 Sep 2006
Price :
$50
*
At a glance
- Originator Johns Hopkins University; University of Michigan Comprehensive Cancer Center; Valentis; Walter Reed Army Institute of Research
- Developer Johns Hopkins University; University of Kentucky; University of Michigan Comprehensive Cancer Center; University of Pennsylvania; Valentis; Walter Reed Army Institute of Research
- Class Antivirals; Cytokine genes; Gene therapies; Interferons
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haemangioendothelioma; Head and neck cancer; HIV infections
Most Recent Events
- 19 Sep 2006 Discontinued - Phase-II for Haemangioendothelioma in USA (unspecified route)
- 19 Sep 2006 Discontinued - Phase-II for Head and neck cancer in USA (Intratumoural)
- 19 Sep 2006 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)